PHARMACEUTICAL COMPOSITIONS FOR CELLULITIS TREATMENT Russian patent published in 2010 - IPC A61K8/49 A61Q19/06 A61K31/50 A61K31/4709 A61K31/444 A61K31/4166 A61K31/4152 A61P17/00 

FIELD: medicine.

SUBSTANCE: invention concerns the application of PDE3B inhibitor specified from the group including: anagrelide, cylostazole, pimobendane, mylrinone, amrinone, olprinone, enoxymone, cylostamide, vesnarinone, trechinsine, 6-[4-(2-benzyl-3-oxo- cyclohex-1-enylamino)-phenyl]-5-methyl-4,5-dihydro-2-N-pyridazine-3-one; 3-{2-[4-(4,4-dimethyl-5-oxo-4,5-dihydro-1-H-pyrazole-3-yl)-2,3-difluoro-phenylamino]-6-oxo-cyclohex-1-enylmethyl}-benzonitrile; 5-{4-[2-(2,6- dichlorobenzyl)-3-oxo-cyclohex-1-enylamino]-2-fluorophenyl}-4,4-dimethyl- 2,4-dihydropyrazole-3-one; 5-[4-(2-benzyl-3-oxo-cyclohex-1-enylamino)-phenyl]-4,4-dimethyl-2,4-dihydropyrazole-3-one; 5-{4-[2-(3-nitrobenzyl)-3-oxo-cyclohex-1-enylamino]-2-fluorophenyl}-4,4-dimethyl-2,4- dihydropyrazole-3-one; 6~[4-(2-benzyl-3-oxo-cyclohex-1-enylamino)-2-fluorophenyl]-5-methyl-4,5-dihydro-2-N-pyridazine-3-one for preparing a pharmaceutical composition for topical or mesotherapeutic cellulitis treatment. Besides a method of cellulitis treatment is disclosed.

EFFECT: extended range of products for cellulitis treatment.

23 cl, 6 ex